July 08, 2025

Waist Size Plus BMI Predicts Mortality

A major long-term study of postmenopausal women found that waist circumference, when assessed alongside BMI, improved mortality risk prediction compared with BMI alone.

Conexiant

July 08, 2025

Mediterranean Diet’s 30-Year Legacy

A sweeping 30-year review confirms the Mediterranean-style diet lowers risks of heart disease, diabetes, cancer, and cognitive decline—while supporting global sustainability.

Conexiant

July 08, 2025

No Safe Level for Processed Foods

A meta-analysis finds no safe level of processed meat, sugary drinks, or industrial trans fats—each linked to increased chronic disease risk.

Conexiant

July 08, 2025

Orforglipron Lowers A1c, Weight in T2D Patients 

A 40-week trial presented at ADA's 85th Scientific Sessions showed that daily oral orforglipron significantly lowered blood sugar and body weight in adults with early type 2 diabetes.

Conexiant

July 08, 2025

Early Gut Microbiota Predicts GDM

Gut microbiota profiles at 11–13 weeks of pregnancy distinguished women who later developed gestational diabetes mellitus with high diagnostic accuracy.

Conexiant

July 08, 2025

Higher BMI, Heart Disease Raise Cancer Risk 

Obesity raises breast cancer risk more sharply in postmenopausal women with heart disease, per data from 168,000+ women in two major European cohorts.

Conexiant

July 08, 2025

New Obesity Framework Reclassifies 1 in 5 Adults

EASO’s expanded obesity definition incorporating waist-to-height ratio and comorbidities reclassifies 18.8% of overweight adults, but mortality benefits remain uncertain.

Conexiant

July 07, 2025

Saliva Test May Signal Diabetes-Linked Metabolic Changes

Salivary enzyme levels tied to AMY1 gene copy number may help indicate type 2 diabetes or prediabetes status, new cross-sectional study suggests.

Conexiant

July 07, 2025

Cagrilintide–Semaglutide Yields Weight, A1c Gains

Once-weekly cagrilintide–semaglutide significantly reduced weight and improved glycemic control in adults with type 2 diabetes in the REDEFINE 2 trial.

Conexiant